ACADIA PHARMACEUTICALS (ACAD) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
ACADIA PHARMACEUTICALS insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $3.4M of ACAD stock on the open market.
Get emailed when insiders cluster-buy stocks like ACAD
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ACAD insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $1.0M | 5 |
| Q2 2026 | — | 0 | $601K | 6 |
| Q1 2026 | — | 0 | $770K | 10 |
| Q4 2025 | — | 0 | $1.0M | 3 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 ACADIA PHARMACEUTICALS INC insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $3.4M. 22 of 24 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ACAD earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 4, 2026 | +0.0% | Sold $433K | +12.5%S&P +1.6% | -2.7% |
| May 6, 2026 | +1.2% | Sold $188K | +0.9%S&P +1.1% | -4.4% |
| Feb 25, 2026 | +5.9% | Sold $162K | +0.2%S&P +0.3% | -15.8% |
| Jan 13, 2026 | -3.7% | None | +1.0%S&P -0.7% | -18.0% |
| Nov 5, 2025 | +4.3% | None | -0.9%S&P -0.7% | +26.7% |
| Aug 6, 2025 | +6.1% | None | +3.2%S&P +0.7% | +3.5% |
| May 7, 2025 | +1.1% | None | +16.4%S&P +1.1% | +29.8% |
| Feb 26, 2025 | +0.7% | None | +1.7%S&P -1.5% | -11.7% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 7SEC | Mark C. SchneyerCFO | Sell Plan | 9,29267,828 held (−12%) | $29.34 | $273K | -32.6% | — |
| Aug 7SEC | Mark C. SchneyerCFO | Sell Plan | 5,84967,828 held (−8%) | $29.00 | $170K | -31.8% | — |
| Aug 7SEC | Mark C. SchneyerCFO | Sell Plan | 5,00077,120 held (−6%) | $29.00 | $145K | -31.8% | — |
| Jul 31SEC | Elizabeth H.z. ThompsonEvp, Head Of Research & Dev | Sell Plan | 16,50819,044 held (−46%) | $26.13 | $431K | -24.3% | — |
| Jul 31SEC | Elizabeth H.z. ThompsonEvp, Head Of Research & Dev | Sell Plan | 5018,994 held (−0%) | $26.17 | $1K | -24.4% | — |
| Jun 29SEC | James KiharaPrincipal Accounting Officer | Sell Plan | 11,42113,088 held (−47%) | $26.08 | $298K | -24.2% | — |
| May 27SEC | James KiharaPrincipal Accounting Officer | Sell | 5,40124,509 held (−18%) | $21.18 | $114K | -6.6% | — |
| May 5SEC | Mark C. SchneyerCFO | Sell Plan | 3,50666,145 held (−5%) | $21.79 | $76K | -9.2% | — |
| May 5SEC | James KiharaPrincipal Accounting Officer | Sell Plan | 1,33229,129 held (−4%) | $21.79 | $29K | -9.2% | — |
| Apr 7SEC | Mark C. SchneyerCFO | Sell Plan | 2,70962,836 held (−4%) | $22.20 | $60K | -10.9% | — |
| Apr 7SEC | James KiharaPrincipal Accounting Officer | Sell Plan | 1,03027,865 held (−4%) | $22.20 | $23K | -10.9% | — |
| Mar 26SEC | Adams Catherine OwenCEO | Sell Plan | 11,64114,803 held (−44%) | $21.47 | $250K | -7.9% | — |
| Mar 26SEC | Mark C. SchneyerCFO | Sell Plan | 4,17757,299 held (−7%) | $21.47 | $90K | -7.9% | — |
| Mar 26SEC | Jennifer J RhodesGeneral Counsel | Sell Plan | 3,84411,280 held (−25%) | $21.47 | $83K | -7.9% | — |
| Mar 26SEC | Elizabeth H.z. ThompsonEvp, Head Of Research & Dev | Sell Plan | 3,4353,280 held (−51%) | $21.47 | $74K | -7.9% | — |
| Mar 26SEC | Mark C. SchneyerCFO | Sell Plan | 3,17160,306 held (−5%) | $21.65 | $69K | -8.6% | — |
| Mar 26SEC | James KiharaPrincipal Accounting Officer | Sell Plan | 1,09726,897 held (−4%) | $21.65 | $24K | -8.6% | — |
| Mar 26SEC | James KiharaPrincipal Accounting Officer | Sell Plan | 83325,852 held (−3%) | $21.47 | $18K | -7.9% | — |
| Mar 26SEC | Mark C. SchneyerCFO | Sell Plan | 3760,269 held (−0%) | $21.72 | $804 | -8.9% | — |
| Mar 26SEC | James KiharaPrincipal Accounting Officer | Sell Plan | 1226,885 held (−0%) | $21.73 | $261 | -9.0% | — |
| Feb 10SEC | Jennifer J RhodesGeneral Counsel | Sell Plan | 6,9507,609 held (−48%) | $23.38 | $162K | -15.4% | — |
| Nov 19SEC | Mark C. SchneyerCFO | Sell Plan | 10,26253,338 held (−16%) | $23.69 | $243K | -16.5% | — |
| Nov 19SEC | James KiharaPrincipal Accounting Officer | Sell Plan | 4,08425,058 held (−14%) | $23.69 | $97K | -16.5% | — |
| Nov 12SEC | James M DalyDirector | Sell | 30,0004,041 held (−88%) | $22.37 | $671K | -11.6% | — |
Insiders at ACADIA PHARMACEUTICALS INC
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Mark C. SchneyerCFO | — | $1.1M | Aug 7, 2026 | — |
| James M DalyDirector | — | $671K | Nov 12, 2025 | — |
| James KiharaPrincipal Accounting Officer | — | $603K | Jun 29, 2026 | — |
| Elizabeth H.z. ThompsonEvp, Head Of Research & Dev | — | $506K | Jul 31, 2026 | — |
| Adams Catherine OwenCEO | — | $250K | Mar 26, 2026 | — |
| Jennifer J RhodesGeneral Counsel | — | $245K | Mar 26, 2026 | — |
ACAD stock: common questions
Are ACADIA PHARMACEUTICALS INC insiders buying ACAD stock?
In the past 12 months, 0 insiders reported open-market purchases of ACAD worth $0.
Are ACADIA PHARMACEUTICALS INC insiders selling ACAD stock?
6 insiders reported sales worth $3.4M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ACAD's 52-week range?
Over the past year ACAD has traded between $19.58 and $30.57. It last closed at $19.78 on Oct 9, 2026.